A Randomized, Double-blind, Placebo-controlled Study of Delandistrogene Moxeparvovec (SRP-9001) for Duchenne Muscular Dystrophy (DMD)
Abroad (travel likely)CompletedPHASE1, PHASE2
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Conditions
Muscular Dystrophy, Duchenne
Locations
- David Geffen School of Medicine at UCLA, Los Angeles, California, United States
- Nationwide Children's Hospital, Columbus, Ohio, United States